Ad Scientiam is proud to announce its collaboration with Abata Therapeutics

Ad Scientiam is proud to announce its collaboration with Abata Therapeutics for the first in human clinical trial of ABA-101, an innovative therapy for progressive multiple sclerosis. Thanks to MSCopilot® , we will utilize digital biomarkers related to the disability status, offering valuable support to this pioneering study.

Share

Ad Scientiam is proud to announce its collaboration with Abata Therapeutics Read the article
en_USEnglish